← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany
NHPN-1010
Also known as: NHPN-1010, HPN-07/NAC, protection pill
Otologic Pharmaceutics
Company
Otologic Pharmaceutics
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 1
Status
Completed
Target Gene
—
Route / Mode
Oral
Confidence
89%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
adult, noise-induced, tinnitus
Trial IDs
1
Mechanism
Oral antioxidant combination was designed as an otoprotectant and neural-repair therapy for acute hearing injury and tinnitus.
Indications
Notes
A long-watched Hough/OMRF-origin program. NHPN-1010 is the HPN-07 plus NAC oral combination; generated HPN-07 and NAC registry intervention rows from NCT02259595 are component arms of this canonical program, not separate HearScape programs. Phase I was completed, but further development remains partner-dependent after a prior license was returned.
Evidence & Sources
4 structured sourcescompany
Supports: canonicalName, company, allCompanies, stage, status, notes
IDs: NHPN-1010
company
Supports: mechanism, indications, route, notes
IDs: NHPN-1010
company
Supports: aliases, stage, status
IDs: NHPN-1010
clinicaltrials
Supports: trialIds, stage, status, route, populationTags, notes
IDs: NCT02259595, HPN-07, NAC
Key Events
Clinical Trials (1)
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2